G Kenet Selected Research

recombinant FVIIa (rFVIIa)

5/2018	In vitro characterization of MOD-5014, a novel long-acting carboxy-terminal peptide (CTP)-modified activated FVII.
9/2017	Estimating the potential cost of a high dose immune tolerance induction (ITI) therapy relative to the cost of a combined therapy of a low dose ITI therapy with bypassing agent prophylaxis.
9/2016	Women with congenital factor VII deficiency: clinical phenotype and treatment options from two international studies.
9/2013	Combined administration of FVIII and rFVIIa improves haemostasis in haemophilia A patients with high-responding inhibitors--a thrombin generation-guided pilot study.
3/2012	On-demand treatment of bleeds in haemophilia patients with inhibitors: strategies for securing and maintaining predictable efficacy with recombinant activated factor VII.
2/2010	Intra-patient variability of thromboelastographic parameters following in vivo and ex vivo administration of recombinant activated factor VII in haemophilia patients. A multi-centre, randomised trial.
9/2009	Lower doses of rFVIIa therapy are safe and effective for surgical interventions in patients with severe FXI deficiency and inhibitors.
7/2009	Concomitant infusion of low doses of rFVIIa and FEIBA in haemophilia patients with inhibitors.
9/2008	Safety update on the use of recombinant factor VIIa and the treatment of congenital and acquired deficiency of factor VIII or IX with inhibitors.
7/2008	Applicability and safety of recombinant activated factor VII to control non-haemophilic haemorrhage: investigational experience in 265 children.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

G Kenet Research Topics

Disease

17	Hemophilia A (Haemophilia) 05/2018 - 04/2000
15	Hemorrhage 05/2018 - 04/2000
3	Thrombosis (Thrombus) 09/2014 - 12/2006
3	Gaucher Disease (Gaucher's Disease) 01/2012 - 07/2003
2	Infections 09/2015 - 01/2006
2	Venous Thromboembolism 09/2014 - 01/2009
2	Stroke (Strokes) 09/2014 - 03/2008
2	Thrombophilia 09/2014 - 11/2008
2	Venous Thrombosis (Deep-Vein Thrombosis) 09/2010 - 03/2008
2	Ischemic Stroke 03/2008 - 06/2000
2	Liver Cirrhosis (Hepatic Cirrhosis) 11/2007 - 07/2006
2	Hepatitis C 11/2007 - 07/2006
2	Fibrosis (Cirrhosis) 11/2007 - 07/2006
2	Liver Diseases (Liver Disease) 07/2006 - 01/2006
2	Wounds and Injuries (Trauma) 09/2001 - 04/2000
1	Menorrhagia 09/2016
1	Antiphospholipid Syndrome (Antiphospholipid Antibody Syndrome) 09/2014
1	Thrombocytopenia (Thrombopenia) 01/2012
1	Cysts 01/2012
1	Neoplasms (Cancer) 09/2010
1	Factor XI Deficiency (Hemophilia C) 09/2009
1	Legg-Calve-Perthes Disease (Perthes Disease) 11/2008
1	Osteonecrosis (Kienbock's Disease) 11/2008
1	Body Weight (Weight, Body) 07/2008
1	Thromboembolism 03/2008
1	Gastroesophageal Reflux (GERD) 11/2007
1	hereditary Thrombophilia 12/2006
1	Chronic Hepatitis C 01/2006
1	Virus Diseases (Viral Diseases) 01/2006
1	Pain (Aches) 03/2003
1	Colitis 09/2001
1	Inflammation (Inflammations) 09/2001
1	Disseminated Intravascular Coagulation 09/2001
1	Crohn Disease (Crohn's Disease) 09/2001
1	Ewing Sarcoma (Sarcoma, Ewing) 06/2001
1	Infertility (Sterility) 06/2001
1	Antithrombin III Deficiency 06/2000

Drug/Important Bio-Agent (IBA)

14	recombinant FVIIa (rFVIIa)FDA Link 05/2018 - 04/2000
5	Factor VIIa (Activated Factor VII)IBA 03/2012 - 04/2000
4	factor V LeidenIBA 09/2014 - 06/2000
3	Factor VIII (Coagulation Factor VIII)IBA 05/2016 - 06/2010
2	Factor VII (Proconvertin)IBA 01/2017 - 09/2016
2	AntithrombinsIBA 09/2014 - 06/2000
2	Protein CIBA 09/2014 - 06/2000
2	Antiphospholipid AntibodiesIBA 09/2014 - 06/2000
2	Protein SIBA 09/2014 - 06/2000
2	Prothrombin (Factor II)IBA 01/2009 - 06/2000
2	AnticoagulantsIBA 03/2008 - 12/2006
2	Biomarkers (Surrogate Marker)IBA 11/2007 - 07/2006
2	Hepatitis C AntibodiesIBA 07/2006 - 01/2006
2	RNA (Ribonucleic Acid)IBA 07/2006 - 01/2006
2	EnzymesIBA 01/2006 - 07/2003
1	Peptides (Polypeptides)IBA 05/2018
1	Cytidine Triphosphate (CTP)IBA 05/2018
1	IronIBA 09/2016
1	Sucrose (Saccharose)IBA 05/2016
1	human F8 protein FDA Link 05/2016
1	AntigensIBA 01/2016
1	EpitopesIBA 01/2016
1	Fibrin Tissue Adhesive (Fibrin Sealant)IBA 03/2015
1	Anticardiolipin AntibodiesIBA 09/2014
1	Lupus Coagulation Inhibitor (Lupus Anticoagulant)IBA 09/2014
1	Thrombin FDA Link 09/2013
1	Blood Proteins (Serum Proteins)IBA 07/2010
1	anti-inhibitor coagulant complexIBA 07/2009
1	DNA (Deoxyribonucleic Acid)IBA 11/2008
1	Collagen Type II (Type II Collagen)IBA 11/2008
1	CollagenIBA 11/2008
1	Low-Molecular-Weight Heparin (Heparin, Low Molecular Weight)IBA 03/2008
1	Heparin (Liquaemin)FDA LinkGeneric 03/2008
1	Proton Pump InhibitorsIBA 11/2007
1	Hyaluronic Acid (Hyaluronan)IBA 07/2006
1	Blood Coagulation Factors (Coagulation Factor)IBA 01/2006
1	Selective Serotonin Reuptake Inhibitors (Serotonin Reuptake Inhibitors)IBA 01/2006
1	Glucosylceramidase (Glucocerebrosidase)IBA 07/2003
1	IodoacetamideIBA 09/2001
1	Thalidomide (Thalomid)FDA Link 09/2001
1	Hemostatics (Antihemorrhagics)IBA 09/2001
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 09/2001
1	Pharmaceutical PreparationsIBA 09/2001
1	Alkylating AgentsIBA 06/2001
1	Cyclophosphamide (Cytoxan)FDA LinkGeneric 06/2001
1	Ifosfamide FDA LinkGeneric 06/2001
1	5,10-methylenetetrahydrofolic acidIBA 06/2000
1	Oxidoreductases (Dehydrogenase)IBA 06/2000

Therapy/Procedure

8	Therapeutics 09/2016 - 07/2009
3	Operative Surgical Procedures 09/2016 - 09/2009
2	Catheters 09/2015 - 09/2010
1	Subcutaneous Injections 05/2018
1	Time-to-Treatment 09/2017
1	Hysterectomy 09/2016
1	Oral Surgery (Maxillofacial Surgery) 03/2015
1	Dental Scaling 01/2012
1	Platelet Transfusion (Blood Platelet Transfusions) 01/2012
1	Crown Lengthening 01/2012
1	Central Venous Catheters 09/2010
1	Duration of Therapy 03/2003
1	Hemostatic Techniques 09/2001
1	Rectal Administration 09/2001
1	Contraindications 09/2001